Those who suffer with respiratory conditions face severe obstacles in performing even the most mundane tasks, such as not being able to climb stairs without stopping to rest or do the dishes. Ventilators can help reduce the effort of breathing by unloading the ancillary respiratory muscles, however they are often heavy, bulky and create even more limitations for the patients that use them. As a response to this unmet need, Breathe Non-Invasive Open Ventilation (NIOV) System technology has been launched by Bayer MaterialScience as a next-generation solution, since it reduces the overall size of the ventilation system and facilitates patient mobility and independence.
The Breathe NIOV System weighs only one-pound and is a non-invasive mechanical ventilator that can be used in both home and institutional settings. Thanks to the use of Makrolon® polycarbonate from Bayer MaterialScience LLC, the portable device integrates a comfortable facial interface that can be worn during exercising and even when talking. Furthermore, the device uses Makrolon® 2858 polycarbonate, which is adequate for medical devices as it can be sterilized and is designed with patient safety in mind.
Larry Mastrovich, CEO and president of Breathe Technologies said in a press release: “We wanted to create a durable and comfortable patient interface, and Makrolon® polycarbonate was the ideal material for our design and intended use. The material’s high quality, biocompatibility and proven performance, along with the support of Bayer’s experts, solidified our choice.”
Richard Aldrich from the Bayer MaterialScience LLC added: “We worked collaboratively with Breathe Technologies to ensure they found the right material for their application. By providing samples, technical data and medical submission support, as well as answering bio-compatibility questions, we were able to help Breathe make the right material choice.”
This is the only ventilation system that can be worn and that has been approved by the FDA for those suffering with respiratory insufficiency, chronic obstructive pulmonary disease (COPD), including Alpha-1 Antitrypsin Deficiency, and in patients with neuromuscular diseases.